Introduction
The promise of adenoviral vectors for therapeutic gene delivery has been partly tempered by the lack of target cell specificity. This has been addressed, firstly, by augmenting tropism, most recently via genetically engineering non-native receptor ligands into the adenovirus fiber protein [1] [2] [3] and secondly, by the use of tissue specific promoter elements which will only drive expression of the foreign transgene in appropriate cell types. [4] [5] [6] [7] [8] [9] Both approaches are limited by the need to identify new receptor ligands or appropriate tissue specific promoters for each cell type. In contrast, the exploitation of a general patho-physiological condition to activate the expression of a therapeutic gene could allow the treatment of a broad spectrum of diseases.
Mammals cope with normal oxygen deficit via a range of homeostatic mechanisms to increase respiration and blood flow. 10 When oxygen levels fall below normal tissue levels, referred to as hypoxia, this activates a tissue stress response. This brings about an increase in oxygen delivery to the tissue via increase in red blood cell levels, increased angiogenesis, as occurs in tumours and wounds, or a decreased oxygen utilisation via metabolic control. The expression of many genes is activated by hypoxia, for example erythropoietin (EPO), a primary regulator of red blood cell production, vascular endothelial growth factor (VEGF), a principal factor involved in angiogenesis, and phosphoglycerate kinase 1 (PGK), a glycolytic enzyme. Activation of all these hypoxically inducible genes involves a cis-acting hypoxia response element (HRE) which can be present as a DNA element in either the 5Ј or 3Ј flanking region.
11- 15 HREs contain one or more binding sites for either hypoxia inducible factor 1 (HIF-1) or other related basic helix-loop-helix PAS (bHLH-PAS) proteins. [16] [17] [18] Regulation appears to be in part via stabilisation of the HIF-1 transcription complex following hypoxic stress (1% O 2 ). 19, 20 HIF-1 DNA binding activity also increases exponentially with decreasing oxygen tensions with half maximal induction between 1.5 and 2% O 2 and a maximum response at 0.5% O 2 . 21 Re-oxygenation (21% O 2 ) causes a rapid decrease in HIF-1 DNA binding activity with a half life less than 15 min. 19, 20 Direct measurements of oxygen tensions in patients' tumours show a range of median oxygen tensions 1.3-3.9% (10-30 mmHg) with readings recorded as low as 0.01% (0.08 mmHg), whereas concentrations in normal tissues are significantly higher, 3.1-8.7% O 2 (24-66 mmHg). More importantly, 82% of all readings taken in solid tumours were less than 0.33% O 2 (2.5 mmHg). 22 Likewise, in arthritic joints, oxygen measurements of 1-6% O 2 were found in the synovial fluid. 23 In peripheral arterial disease, the occlusion of the blood supply results in extreme hypoxia and ultimately anoxia and tissue gangrene. 24 Therefore, HIF-1 is a ubiquitously expressed transcription factor known to be active within a pathophysiologically relevant range of oxygen concentrations.
Hypoxia response elements derived from the murine PGK and human EPO genes and driving the expression of therapeutic genes, displayed a hypoxically controlled increase in gene expression in stable cell lines and in vivo in tumour xenografts 25, 26 in rat and rabbit cardiac mus- cle 27 and in encapsulated mouse skeletal muscle lines. 26 An enhancer present in the EPO gene was also found to boost expression from a constitutive promoter. 28 These data suggest that it may be possible to use the hypoxiasignalling pathway to activate gene expression selectively. However, the maximum levels of expression, the degree of induction and the use of more potent gene therapy vectors were not well characterised. We now describe for the first time an adenoviral vector, Ad.OBHRE, that confers highly inducible gene expression in response to hypoxia in a range of cell lines, which include a primary human skeletal muscle cell line. In addition the maximum achievable expression under hypoxia is similar to that achieved by the efficient CMV early promoter. Adenoviruses are potent tools for gene therapy because of the ease of production and the gene transfer efficiency but their broad host range needs to be counteracted by tissue targeting. The ability to regulate expression in adenoviral vectors by a patho-physiological switch now opens up possibilities for generating new treatments for disorders characterised by hypoxia such as peripheral arterial disease, solid tumours, arthritis and severe anaemia.
Results
Generation of an adenoviral vector containing hypoxia response elements In a previous study we have identified an optimised hypoxia responsive promoter. 45 Hypoxia response elements (HRE) derived from known hypoxia regulated genes including enolase, lactate dehydrogenase, EPO, and PGK1, were placed upstream of an SV40 minimal promoter controlling the expression of a luciferase reporter gene. A hypoxia responsive promoter containing sequences derived from the murine PGK1 promoter gave the best induction ratios of greater than 100-fold at 0.1% O 2 . The induced expression level was as high as that obtained from the cytomegalovirus immediate-early (CMV IE). This enhancer/minimal promoter configuration is referred to as OBHRE.
The complete OBHRE expression cassette ( Figure 1 ) was inserted into the adenoviral shuttle vector where luciferase was replaced with the ␤-galactosidase (␤-gal) reporter gene. The recombinant adenovirus (Ad.OBHRE) was generated by homologous recombination between the shuttle vector and the purified right arm of adenovirus serotype 5, which were co-transfected into 293A cells. Figure 2 where a dose response in the hypoxic induction of ␤-gal expression can be seen giving 2.7-fold and 14-fold induction at 5% and 0.1% oxygen tensions, respectively. This oxygen concentration-dependent expression probably reflects the increase in HIF-1 protein stability as the oxygen tension is decreased. 21 Adenovirus transduces cells transiently in a non-integrative, episomal manner. Increasing the multiplicity of infection of the vector will result in an elevation of the number of recombinant adenoviral genomes per cell. This could interfere with the regulation if relevant factors become diluted by excess template. To test this the cell lines were transduced with increasing amounts of both Ad.OBHRE and Ad.CMV and the hypoxically induced expression of ␤-gal was examined. Data are shown for the HT1080 cell line in Figure 2 . Although increasing the MOI of the virus from 20 to 100 increases the level of expression from both the Ad.CMV and Ad.OBHRE transduced cells the actual fold induction from Ad.OBHRE remains constant. At the higher MOI (100) the induced expression from Ad.OBHRE transduced cells approached that of Ad.CMV. These data indicate that the MOI is not critical to achieve regulation and efficient induced expression although for some therapeutic genes the higher basal level observed at high multiplicity may not be desirable.
Pharmacological modulation of induction in Ad.OBHRE transduced cells
Numerous reports provide data on the ability of chemical agonists, which are apparently able to act through hypoxia response elements, to mimic the hypoxic response. 15, 29 We examined whether two such agents, desferrioxamine and cobalt chloride, were able to induce reporter expression in the adenoviral gene delivery system. When Ad.OBHRE transduced cells were exposed to cobalt chloride (Co) or desferrioxamine (DFO) a marked increase in the expression of ␤-gal was observed (Table  1) . Induction levels achieved with both DFO and Co were generally lower than that observed for hypoxia (0.1% O 2 ) for all the cell lines examined, except for MCF-7 where DFO resulted in a 28-fold induction of ␤-gal expression compared with 16-fold using 0.1% oxygen (Table 1) . Interestingly, DFO induced expression in virtually all the tumour lines examined to a greater degree than Co with the exception of the HS 906 Mu connective tissue cell line which was induced to a similar degree of 5.5-and fourfold with Co and DFO, respectively. As shown in Table  1 , the different cell lines displayed variations in the induction ratios, this is likely to be attributable to the inherent ability of different cell types to respond to hypoxia. However, all the cell lines tested gave an induced level of ␤-gal expression under 0.1% oxygen tension when transduced with Ad.OBHRE which approached that of the Ad.CMV transduced cells ( Figure 2 ).
Primary human skeletal muscle transduced with Ad.OBHRE display a high level of hypoxic induction Skeletal muscle is readily accessible for gene transfer via a range of gene delivery vehicles that include recombinant adenovirus, therefore making it an attractive target for a number of gene therapy approaches. 30 We have already shown that a range of human cell lines including the human connective tissue, Hs 906(D).Mu are capable of elevating the expression of ␤-gal in Ad.OBHRE transduced cells in response to hypoxic and Co/DFO induction. We next transduced primary skeletal muscle cells (SkMC) with an MOI of 100 of both Ad.OBHRE and Ad.CMV. We observed a 50-fold hypoxic (0.1% O 2 ) induction of ␤-gal expression in Ad.OBHRE transduced cells which approached the level of expression from the CMV promoter in the Ad.CMV transduced cells ( Figure  3 ). In addition, we examined whether DFO and Co could induce expression at concentrations of 150 M. Inductions of 33-and 17-fold were observed for Co and DFO, respectively, in the Ad.OBHRE transduced SkMC cells (Figure 3 ). These data are the first report of hypoxic induction of the HRE in primary human skeletal muscle. The inducibility of Ad.OBHRE appeared to be most marked in the primary tissue and we have observed similar high efficiencies in human primary hematopoetic cells (Griffiths et al, manuscript submitted) . This may reflect a difference in the levels or activity of relevant transcription factors and this is currently under investigation.
Discussion
We describe a physiologically regulated adenoviral vector system that can be used to target therapeutic gene expression to pathologies typified by hypoxia. Furthermore we demonstrate the potential to regulate this gene expression system using small molecule mimics thereby extending its utility. The induced expression levels of a heterologous reporter gene approached that obtained using the CMV IE promoter for all the cell types examined. Notably, we obtained the highest induction ratio (50-fold) in primary human skeletal muscle cells in response to hypoxic stimulation at 0.1% oxygen tension.
This degree of hypoxia is well within the range of that found in ischaemic tissues in vivo. 22, 31, 32 The low basal activity at atmospheric oxygen concentrations and low activity at 5% O 2 would suggest minimal activity in oxygen tensions found in healthy tissues. In addition to decreasing oxygen tension, we observed that increasing the MOI of the virus elevated the level of transgene expression. Therefore, the final level of expression from this adenoviral inducible system may be controlled by the degree of hypoxic stress together with the relative amount of the vector.
We have additionally shown that the hypoxia-signalling pathway in the context of this adenoviral system is able to respond to mimics of hypoxia including desferrioxamine and cobalt. Desferrioxamine is a pharmacological agent, which is currently used for the treatment of thalassaemia, neuroblastoma and Alzheimer's disease. [33] [34] [35] [36] This suggests the possibility of augmenting the hypoxia response or of extending the therapeutic range of the hypoxia-signalling pathway beyond tissues that are pathologically typified by hypoxia. A typical scenario for example would be if erythropoietin were the therapeutic gene under control of a hypoxia responsive promoter. 26 The application of desferrioxamine in an acute phase of low haematocrit would permit an erythropoietin boost whilst chronic problems would be managed physiologically via hypoxic control. Other compounds that mimic hypoxia might also be useful for example, mersalyl that increases HIF-1 activity via the IGF 1 receptor. 37 It has also been suggested that insulin has an effect on the HIF-1 pathway although we have not observed this at the physiological insulin levels that are used to culture some of our tumour cell lines such as OVCAR-3. 38 The broad tropism of adenovirus relative to other viral vector systems such as the murine leukaemia virus (MLV)-based retroviral system means that targeting gene expression is particularly important. Targeting via structural changes in the adenovirus fiber protein have largely lead to an extension of the tropism to cell types which are normally only weakly infected by the virus. 1, 39 Restriction of recombinant adenoviral gene expression has been achieved using tissue specific promoters. [4] [5] [6] [7] [8] [9] However, such adenoviral systems often suffer from high basal expression in non-specific cell types, relatively poor tissue-specific inducibility or there may be negative elements in the adenoviral genome that limit the use of certain tissue-specific promoters. 8, 40 These are important issues since the therapeutic window for certain proteins may be such that expression below or above certain thresholds would be ineffective or toxic to unaffected tissues. The prescriptive for a transcriptionally targeted gene delivery system would be low basal activity with high inducible expression levels. These parameters are met by the Ad.OBHRE adenoviral system. Exploiting the hypoxia response also circumvents the requirement for an exogenously supplied activator/repressor as required in the currently available inducible systems such as the tetracycline and rapamycin approaches. 41, 42 In addition the use of such non-mammalian regulators poses delivery and immunogenicity problems for in vivo gene therapy.
Ad.OBHRE was particularly effective in primary human skeletal muscle cells, which displayed a 50-fold induction ratio of the heterologous reporter gene. Skeletal muscle is readily accessible for in vivo gene transduction via intramuscular injection of a variety of vectors, including adenovirus. 30, 43 Genetically modified muscle cells can efficiently secrete recombinant proteins into the systemic circulation, potentially providing a platform for gene therapy not only for chronic limb ischaemia caused by peripheral arterial disease but also for serum protein deficiencies such as haemophilia and diabetes. In summary, we have constructed a novel adenoviral vector where expression of the transgene is efficiently regulated by hypoxia. We have demonstrated that in this system the hypoxic switch functions in a range of cell types, including primary human skeletal muscle cells, giving low basal promoter activity coupled with high levels of hypoxically induced expression. The switch responds to both low oxygen tension and chemical mimics of hypoxia. The activity of the hypoxia mimics extends the therapeutic range of this system beyond pathologies typified by hypoxia and could be used in a combined therapeutic approach to augment the induction via hypoxia. By using the Ad.OBHRE vectors one can now envisage delivering therapeutic genes such as VEGF, angiostatin and erythropoietin to produce specific, regulated correction of diseases such as, respectively, peripheral arterial disease, cancer and anaemia.
Experimental protocol
Cells and reagents MCF-7 human breast carcinoma, HT1080 human fibrosarcoma, C2C12 (ECACC) murine muscle myoblast, Hs 906(D) Mu (ATCC) connective tissue and 293A human embryonic kidney (Quantum Biotechnologies, Laval, Quebec, Canada) cell lines were maintained in Dulbeccos modified Eagle's medium supplemented with 10% (v/v) foetal calf serum, 2 mm glutamine. The NIH-OVCAR-3 cell line was grown in RPMI-1640 medium supplemented with 2 mm glutamine, 1.5g/l NaHCO 3 , 4.5g/l glucose, 10 mm Hepes, 1 mm sodium pyruvate, 10 g/ml insulin and 20% (v/v) FBS. Primary human skeletal muscle cells (MyoPack-SkMC) were obtained from Clonetics (TCS Biologicals, Buckingham, UK) and cultured according to the distributor's recommendations.
For transient assays the media was also supplemented with 1% (v/v) penicillin/streptomycin antibiotics. All tissue culture media/solutions were purchased from Sigma (Dorset, UK).
Adenoviral vector construction
The Ad.OBHRE first generation recombinant adenoviral vector (E1/E3 deleted) was constructed as follows. An oligonucleotide was constructed based on the hypoxia response element from the murine phosphoglycerate kinase 1 5Ј flanking sequence (−307/−290) 14 with 5Ј Nhel and 3Ј Xbal compatible ends: 5Ј CTAGAGTCGTGCA GGACGTGACATC/TAGTGTCGTGCAGGCATC/TAGT GTCGTGCAGGACGTGACATC3Ј, 3ЈTCAGCACGTCCTG CACTGTAG/ATCACAGCACGTCCGTAG/ATCACAGC ACGTCCTGCACTGTAGGATC 5Ј. This oligonucleotide was cloned into the Nhel site of the pGL3promoter vector from Promega.
The firefly luciferase gene in pGL3promoter was replaced by the bacterial ␤-galactosidase encoding gene (␤-gal) and the resulting OBHRElacZ cassette removed as a Kpnl-Sall fragment and cloned into the pADBN transfer vector (Quantum Biotechnologies) (Figure 1) . Recombinant Ad.OBHRE was generated by homologous recombination between the adenoviral shuttle vector described above and the purified right arm of the adenovirus serotype 5 virus (Quantum Biotechnologies) co-transfected by the calcium phosphate method into 293A cells. Following transfection plates were overlaid with agar and initial plaques were harvested and screened for ␤-gal enzymatic activity. Plaques expressing functional ␤-gal were further purified through three subsequent rounds of plaque purification. A recombinant adenovirus expressing a ␤-gal reporter gene under the control of the CMV promoter (nucleotides −834/−216, Genbank K03104), Ad.CMV was used as a control (Quantum Biotechnologies). Adenoviral stocks were purified using the Arklone P fluorocarbon compound according to previously described protocols. 44 Viral titre, expressed as multiplicity of infection (MOI) was determined by standard plaque-forming unit (p.f.u.) and limiting dilution assays on 293A cells.
Adenoviral transductions and reporter assays
Exponentially growing cells were transduced with an MOI of 20-100 of the recombinant adenovirus in DMEM supplemented with 5% FCS for 90 min with frequent gentle shaking for 6-8 h before the virus was removed and replaced with fresh media appropriate for the cell line. Transduced cells were then either incubated for 16 h under normoxic (21% O 2 , 5% CO 2 , 75% N 2 ), intermediate (5% O 2 , 5% CO 2 , 75% N 2 ) or hypoxic (0.1% O 2 , 5% CO 2 , 75% N 2 ) conditions using multigas incubators purchased from Heto, or in the presence of 150 m of either cobalt chloride or desferrioxamine (Sigma).
␤-Galactosidase chemiluminescent reporter assays were carried out using the Galacton-Plus (Tropix Inc, Warrington, UK) reporter assay system together with a Dynex Technologies MRX Microtiter plate luminometer. A ␤-gal standard (Sigma) was included in each assay to ensure the relative light units (RLU) of each sample were within the linear range of the assay. All reporter assays were carried out in triplicate and normalised to the protein concentration in the cell lysate.
Protein assays were carried out using the detergent compatible protein assay kit (BioRad, York, UK) together with a Dynex Technologies MRX Plate reader using a bovine serum albumin protein standard.
Histochemical staining for ␤-galactosidase activity was carried out by first washing the cells with PBS and fixing with buffered neutral formalin (BDH/Merck, Leicester, UK). After 5 min the formalin was removed and cells were washed twice with PBS before replacing with X-Gal stain (5 mm K 3 Fe(CN) 6 , 5 mm K 3 Fe(CN) 6 , 2 mm MgCl 2 , 1 mg/ml 5-bromo-4-chloro-3-indolyl-␤-d-galactopyranoside).
